Májcirrózis
Sipeki, N., Antal-Szalmás, P., Lakatos, P., Papp, M.: Immune dysfunction in cirrhosis.
World J. Gastroenterol 20 (10), 2564-2577., 2014. IF: 2,369
Papp, M.: Response to Low L-Ficolin associated with disease severity during sepsis in adult ICU patients.
Liver Int 37 (9), 1410., 2017. IF: -
Dinya, T., Tornai, T., Vitális, Z., Tornai, I., Balogh, B., Tornai, D., Antal-Szalmás, P., Sümegi, A., Andrikovics, H., Bors, A., Tordai, A., Papp, M.: Functional polymorphisms of innate immunity receptors are not risk factors for the non-SBP type bacterial infections in cirrhosis.
Liver Int 38 (7), 1242-1252., 2018. IF: 4,116 (2016)
Földi, I., Tornai, T., Tornai, D., Sipeki, N., Vitális, Z., Tornai, I., Dinya, T., Antal-Szalmás, P., Papp, M.: Lectin-complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections.
Liver Int 37 (7), 1023-1031., 2017. IF: 4,116 (2016)
Papp, M., Tornai, T., Vitális, Z., Tornai, I., Tornai, D., Dinya, T., Sümegi, A., Antal-Szalmás, P.: Presepsin teardown: Pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis.
World J. Gastroenterol 22 (41), 1-14., 2016. IF: 3,365
Tornai, T., Vitális, Z., Sipeki, N., Dinya, T., Tornai, D., Antal-Szalmás, P., Karányi, Z., Tornai, I.,Papp, M.: Macrophage activation marker, soluble CD163 is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection.
Liver Int 36 (11), 1628-1638., 2016. IF: 4,116
Papp, M., Sipeki, N., Vitális, Z., Tornai, T., Altorjay, I., Tornai, I., Udvardy, M., Fechner, K., Jacobsen, S., Teegen, B., Sümegi, A., Veres, G., Lakatos, P., Kappelmayer, J., Antal-Szalmás, P.: High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.
J. Hepatol 59 (3), 457-466., 2013. IF: 10,401
Papp, M., Vitális, Z., Altorjay, I., Tornai, I., Udvardy, M., Hársfalvi, J., Vida, A., Kappelmayer, J., Lakatos, P., Antal-Szalmás, P.: Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections.
Liver Int 32 (4), 603-611., 2012. IF: 3,87
Vitális, Z., Altorjay, I., Tornai, I., Palatka, K., Kacska, S., Pályu, E., Tornai, D., Udvardy, M., Hársfalvi, J., Dinya, T., Veres, G., Lakatos, P., Papp, M.: Phenotypic polymorphism of haptoglobin: A novel risk factor for the development of infection in liver cirrhosis.
Hum. Immunol 72 (4), 348-354., 2011. IF: 2,837
Altorjay, I., Vitális, Z., Tornai, I., Palatka, K., Kacska, S., Farkas, G., Udvardy, M., Hársfalvi, J., Dinya, T., Orosz, P., Lombay, B., Pár, G., Pár, A., Csak, T., Osztovits, J., Szalay, F., Csepregi, A., Lakatos, P., Papp, M.: Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis.
J. Hepatol 53 (3), 484-491., 2010. IF: 9,334
Papp, M., Norman, G., Vitális, Z., Tornai, I., Altorjay, I., Földi, I., Udvardy, M., Shums, Z., Dinya, T., Orosz, P., Lombay, B., Pár, G., Pár, A., Veres, G., Csak, T., Osztovits, J., Szalay, F., Lakatos, P.: Presence of Anti-Microbial Antibodies in Liver Cirrhosis: A Tell-Tale Sign of Compromised Immunity?.
PloS One 5 (9), e12957-1-e12957-9., 2010. IF: 4,411
Primér szklerotizáló kolangitisz
Tornai, T., Pályu, E., Vitális, Z., Tornai, I., Tornai, D., Antal-Szalmás, P., Norman, G., Shums, Z., Veres, G., Dezsőfi, A., Pár, G., Pár, A., Orosz, P., Szalay, F., Lakatos, P., Papp, M.: Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.
World J. Gastroenterol 23 (29), 5412-5421., 2017. IF: 3,365 (2016)
Tornai, T., Tornai, D., Sipeki, N., Tornai, I., Alsulaimani, R., Fechner, K., Roggenbuck, D., Norman, G., Veres, G., Pár, G., Pár, A., Szalay, F., Lakatos, P., Antal-Szalmás, P., Papp, M.: Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
Sci. Rep 8 (1), 1-11., 2018. IF: 4,259 (2016)
Gyulladásos bélbetegségek
Papp, M., Lakatos, P.: Serological studies in inflammatory bowel disease: how important are they?.
Curr. Opin. Gastroenterol 30 (4), 359-364., 2014. IF: 4,289
Kovács, G., Sipeki, N., Suga, B., Tornai, T., Fechner, K., Norman, G., Shums, Z., Antal-Szalmás, P., Papp, M.: Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.
PLoS One 13 (3), 1-18., 2018. IF: 2,806 (2016)
Lakatos, P., Sipeki, N., Kovács, G., Pályu, E., Norman, G., Shums, Z., Golovics, P., Lovász, B., Antal-Szalmás, P., Papp, M.: Risk matrix for prediction of disease progression in a referral cohort of patients with Crohn's disease.
J. Crohns. Colitis 9 (10), 891-898., 2015. IF: 6,585
Sipeki, N., Dávida, L., Pályu, E., Altorjay, I., Hársfalvi, J., Antal-Szalmás, P., Szabó, Z., Veres, G., Shums, Z., Norman, G., Lakatos, P., Papp, M.: Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
World J. Gastroenterol 21 (22), 6952-6964., 2015. IF: 2,787
Papp, M., Sipeki, N., Tornai, T., Altorjay, I., Norman, G., Shums, Z., Roggenbuck, D., Fechner, K., Stocker, W., Antal-Szalmás, P., Veres, G., Lakatos, P.: Rediscovery of the anti-pancreatic antibodies and evaluation of their prognostic value in a prospective clinical cohort of Crohn's patients: The importance of specific target antigens (GP2 and CUZD1).
J. Crohns Colitis 9 (8), 659-668., 2015. IF: 6,585
Kiss, L., Papp, M., Lovász, B., Végh, Z., Golovics, P., Janka, E., Varga, É., Szathmári, M., Lakatos, P.: High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: A marker for patient classification?.
Inflamm. Bowel Dis 18 (9), 1647-1654., 2012. IF: 5,119
Lakatos, P., Kiss, L., Palatka, K., Altorjay, I., Antal-Szalmás, P., Pályu, E., Udvardy, M., Molnár, T., Farkas, K., Veres, G., Hársfalvi, J., Papp, J., Papp, M.: Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease.
Inflamm. Bowel Dis 17 (3), 767-777., 2011. IF: 4,855
Papp, M., Lakatos, P., Hársfalvi, J., Farkas, G., Palatka, K., Udvardy, M., Molnár, T., Farkas, K., Nagy, F., Veres, G., Lakatos, L., Kovács, Á., Dinya, T., Kocsis, K., Papp, J., The Hungarian IBD Study Group, Altorjay, I.: Mannose-binding lectin level and deficiency is not associated with inflammatory bowel diseases, disease phenotype, serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort.
Hum. Immunol 71 (4), 407-413., 2010. IF: 2,872
Lakatos, P., Altorjay, I., Szamosi, T., Palatka, K., Vitális, Z., Tumpek, J., Sipka, S., Udvardy, M., Dinya, T., Lakatos, L., Kovács, Á., Molnár, T., Tulassay, Z., Miheller, P., Barta, Z., Stocker, W., Papp, J., Veres, G.,Papp, M., The Hungarian IBD Study Group: Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behaviour, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.
Inflamm. Bowel Dis 15 (3), 365-374., 2009. IF: 4,643
Papp, M., Altorjay, I., Dotan, N., Palatka, K., Földi, I., Tumpek, J., Sipka, S., Udvardy, M., Dinya, T., Lakatos, L., Kovács, Á., Molnár, T., Tulassay, Z., Miheller, P., Norman, G., Szamosi, T., Papp, J., The Hungarian IBD Study Group, Lakatos, P.: New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.
Am. J. Gastroenterol 103 665-681., 2008. IF: 6,444
Cöliakia
Papp, M., Földi, I., Altorjay, I., Pályu, E., Udvardy, M., Tumpek, J., Sipka, S., Korponay-Szabó, I., Nemes, É., Veres, G., Dinya, T., Tordai, A., Andrikovics, H., Norman, G., Lakatos, P.: Anti-microbial antibodies in celiac disease: Trick or treat?.
World J. Gastroenterol 15 (31), 3891-3900., 2009. IF: 2,092